Skip to main content
Fig. 3 | Alzheimer's Research & Therapy

Fig. 3

From: Normal levels of KIF5 but reduced KLC1 levels in both Alzheimer disease and Alzheimer disease in Down syndrome: evidence suggesting defects in anterograde transport

Fig. 3

KIF5 levels were not changed in the frontal cortex of AD-DS brain. a Western blotting analysis of KIF5 levels in protein extracts from the frontal cortex of patients with AD-DS and C/AD-DS. fl-hAPP was also probed. β-Actin and GAPDH were each used as internal loading controls. b Quantitation and statistical analysis of the levels of fl-hAPP in AD-DS and C/AD-DS. c Quantitation and statistical analysis of the levels of KIF5 family members in AD-DS and C/AD-DS. d Spearman’s correlation analysis of KIF5 members in the combined C/AD-DS and AD-DS samples, with the red dotted line marking the 95% confidence interval. Insert with the same diagram indicates the distribution of C/AD-DS and AD-DS samples. e Quantitation and statistical analysis of the levels of KIF5 family members in females and males from AD-DS (DS) and C/AD-DS (C/DS). f Spearman’s correlation analysis between age and the levels of KIF5 members in AD-DS and C/AD-DS. n = 19 and 21 for C/AD-DS and AD-DS patients, respectively, Mann-Whitney test in b, c, and e. ***P < 0.001 unless stated. n.s., non-significant; F, female; M, male

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193